6th Genome Editing Therapeutics Summit
2025-09-29 - 2025-10-01 | Wyndham Boston Beacon Hill, 5 Blossom St, Boston, MA, 02114, United States
With baby KJ successfully receiving the world’s first personalized CRISPR therapy, alongside continued innovation across in vivo and base editing, and rapid ex vivo clinical progress, the genome editing field stands at a pivotal juncture.
To mark this definitive CRISPR milestone, the 6th Genome Editing Therapeutics Summit returns to Boston to celebrate ongoing progress, whilst also tackling end-to-end challenges from discovery through to commercial strategy.
Unite with the industry’s leading minds, as they advance delivery specificity, spearhead in vivo editing, ensure precise targeting, improve translatability, and build robust clinical strategies to unlock precise, durable and safe therapeutics.
The 2025 Expert Speaker Line-up Includes:

Kiran Musunru, Professor, Translational Research, University of Pennsylvania
TJ Cradick, Chief Technology Officer, HuidaGene Therapeutics
Nageswara Kollu, Senior Director, Gene Therapy, Apellis Pharmaceuticals
Alexandria Petrusich, Vice President, Clinical Science, Prime Medicine
Bradley Ringeisen, Executive Director, Innovative Genomics Institute
Chris Brown, Vice President, Discovery, Metagenomi
Anjulika Chawla, Vice President, Medical Affairs, Clinical Lead, Bluebird Bio

Alongside 20+ data-driven presentations, this year’s program will feature a deep-dive workshop dedicated to the impact of baby KJ, led by Innovative Genomics Institute, HuidaGene Therapeutics and the University of Pennsylvania.
Ensure you are part of the most anticipated gene editing event of the year!
To know more visit: https://ter.li/rd7cax

LEAP TA: Life Sciences
2025-09-29 - 2025-10-01 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
As 2025 shapes up to be a transformative year for talent acquisition in life sciences, the 7th LEAP TA: Life Sciences returns to Boston, MA this September (29 – October 1), uniting over 120 senior TA professionals from industry pioneers including Pfizer, AbbVie, Bristol Myers Squibb, Bayer, Edwards Lifesciences, The Jackson Laboratory, and more.
This is the only event dedicated entirely to helping biopharma reimagine how they attract, engage, and retain top talent in an increasingly complex hiring landscape. In a time of political uncertainty, evolving regulations, and rapid scientific advancement, hiring in life sciences has never been more challenging, or vital to long-term success.
Over three high-impact days, uncover how TA leaders are:

Navigating visa challenges, DEI pushback, and new workforce expectations
Leveraging AI, redefined employer branding, and technology to build future-ready teams
Driving value-driven recruitment in the face of political and market disruption
Adapting to shifting skills requirements through innovative sourcing strategies

From small biotechs to global pharma giants, this event spotlights real-world case studies and actionable insights from across the industry, all designed to equip you with the tools to compete for niche, scientific, and technical talent in today’s market.
Whether you’re looking to streamline time-to-fill, reduce turnover, or build a more resilient and diverse talent pipeline, LEAP TA: Life Sciences offers a unique opportunity to step back from day-to-day execution, connect with your peers, and rethink what’s possible in TA.
Join the most forward-thinking talent acquisition leaders in life sciences to shape the future of hiring in 2025 and beyond.

9th MASH Drug Development Summit
2025-09-29 - 2025-10-01 | Hyatt Regency Boston / Cambridge, 575 Memorial Dr, Cambridge, MA, 02139, United States
The 9th MASH Drug Development Summit is the definitive meeting for pharma and biotech leaders advancing the next generation of therapies for MASH. With the approval of Rezdiffra signaling a new era, the race is on to deliver more effective, patient-centered treatments.
This year, dive into novel mechanisms of action, non-invasive biomarkers, and strategic combination and sequential therapies. Hear from experts at Eli Lilly, Pfizer, Takeda, Madrigal, Akero, 89 Bio, and more as they share cutting-edge research and clinical strategies targeting diverse patient populations.
Join 60+ MASH scientists and drug developers, gain critical insights, and build meaningful collaborations over 10+ hours of dedicated networking. Don’t miss the Pre-Conference Combination & Sequential Therapy Day for a focused deep dive into emerging treatment approaches.
Find out more now: https://ter.li/d9r0pm

2nd Raw Materials for Cell & Gene Therapy Summit
2025-10-07 - 2025-10-09 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
Unlock the future of cell and gene therapy manufacturing at the 2nd Raw Materials for Cell & Gene Therapy Summit. This is your exclusive opportunity to hear directly from regulatory and standards leaders such as Andrew Sarafanov (FDA) and Rebecca Potts (USP), as they share the latest thinking on BLA review expectations, raw material characterization, and the evolving global standards landscape.
With the cell and gene therapy industry facing increasing complexity and supply chain uncertainty, top innovators from Vertex, Genentech, and Bristol Myers Squibb will reveal how they’re reengineering supplier strategies, through dual sourcing, co-development, and rigorous vendor qualification.
Find out more: https://ter.li/yesw2g
Explore real-world solutions to qualification challenges and variability risks with insights from Ultragenyx, Abeona Therapeutics, and Metagenomi. Through hands-on workshops, strategic roundtables, and high-impact networking, you’ll walk away with the connections and frameworks needed to strengthen your quality programs and stay ahead of regulatory expectations. The time to align, adapt, and advance is now.

7th Gene Therapy Analytical Development Summit
2025-10-21 - 2025-10-23 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
Driving Analytical Excellence from Pre-IND Through BLA for Next-Generation Gene Therapies
Returning to Boston this October, the 7th Gene Therapy Analytical Development Summit is the industry’s definitive meeting for advancing assay development and analytical strategy across the gene therapy lifecycle. As gene therapy platforms expand beyond AAV to encompass mRNA, CRISPR-based modalities, LNPs, and novel capsids, analytical teams must evolve in parallel to meet growing regulatory scrutiny and technical complexity.
This summit brings together analytical development, QC, and regulatory experts to share practical insights on validating potency assays, genome integrity, and advanced characterization tools to ensure product consistency, safety, and regulatory readiness from early development through to BLA and commercial launch.
With expert contributions from leaders at Beam Therapeutics, Sarepta, Astellas, Spark Therapeutics, Adverum, REGENXBIO, and GenSight Biologics, attendees will explore real-world solutions to persistent challenges in full or empty capsid quantification, aggregation profiling, stability assay design, and assay transfer into GMP environments.
Featured speakers include Johnson Varghese, Vice President of Analytical Sciences at Beam Therapeutics, sharing phase-appropriate validation strategies, and Sue Duan, Head of Analytical Development at Astellas, who will discuss genome integrity testing across multiple vector platforms. Also presenting are Uditha DeAlwis of Sarepta Therapeutics and Vanessa Strings-Ufombah from Adverum Biotechnologies, offering unique perspectives on aligning assay strategies with global regulatory expectations.
Attendees will gain exposure to cutting-edge techniques including long-read sequencing, digital PCR, analytical ultracentrifugation, and mass photometry, with a focus on integrating these tools into QC-ready workflows that meet IND, BLA, and RMAT requirements.
With two technical tracks, this event delivers unmatched depth across bioassays, molecular analytics, and physicochemical characterization, empowering you to optimize existing platforms or develop robust analytics for new therapeutic modalities.
Whether refining potency assays, reducing batch variability, or preparing for regulatory submission, this is your opportunity to benchmark with peers and shape the future of gene therapy analytics in 2025 and beyond.
Download the Brochure Here for More Information: https://ter.li/wld1o2

3rd Spatial Biology for Drug Development Summit
2025-10-22 - 2025-10-23 | The Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116, United States
The 3rd Spatial Biology for Drug Development Summit is your opportunity to come together with leading biopharma experts to address these challenges within the spatial biology space head-on.

Across an intensive 2-day agenda, you’ll explore practical solutions to issues spanning data infrastructure, multi-omics integration, standardization, scalability, and translation into the clinic. This year’s forum will equip you with the latest data-driven strategies to not only overcome obstacles but to maximize the value of spatial biology for deeper disease insights, robust target identification, biomarker discovery, and more.
Find out more here: https://ter.li/otrpyk
Spatial biology is at a turning point. Rapid advances in resolution, sensitivity, and multi-omics integration are delivering more robust and clinically meaningful insights than ever before. Recent collaborations and investments, such as GSK’s partnership with Relation Therapeutics and Sanofi’s expanded partnership with Owkin, highlight the strong momentum and confidence building across the sector. Yet, challenges around data standardization, integration, scalability, and cost continue to limit widespread adoption, particularly among small and mid-sized biopharma companies.
No other meeting will give you the chance to connect with 70+ spatial biology experts for *free and take away fresh, actionable data from AstraZeneca, Takeda, AbbVie, Genentech, Amgen, Pfizer, Johnson & Johnson, and many more – the exact people you need to meet to move your work forward.
Join the spatial biology community (for free) here: https://ter.li/fvnrcc

13th IMPACCT Real-World Evidence Summit
2025-10-27 - 2025-10-29 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
With CMS introducing new guidance for RWD studies, the FDA announcing a new RWE Center, and RWD becoming more accessible, it is clear that RWE will play an increasingly pivotal role in the drug development lifecycle. But uncertainties still remain for the experts applying RWE.
Returning to Boston, the 13th IMPACCT Real-World Evidence Summit is the only industry-focused meeting dedicated to uniting RWE experts to consolidate and optimize their RWE strategies. Join 140+ industry pioneers from top pharma and biotech companies, as they share real-world case studies, the latest industry insights, and transformative strategies to upskill your team with the knowledge to advance your RWE utility.
Find out more
What Can You Expect?

Hear how Pfizer are using AI to refine data quality through optimized data generation, data pipeline automation, and data augmentation.
Identify key tokenization methods to ensure consistency, interoperability, and improved data utility for regulatory and payer decision making with AstraZeneca.
Learn how Abbvie are empowering their value and evidence teams with timely insights to support market access and strategic planning.
Build a centralized evidence strategy that aligns your cross-functional teams and ensures consistent objectives with Otsuka and Ionis Pharmaceuticals.

Discover the extensive list of sessions, speakers and case studies in our agenda!
Seize your opportunity to gain invaluable industry insights, address challenges and foster connections, to perfect your data-quality and enhance your RWE approaches.

8th TPD & Induced Proximity Summit
2025-10-27 - 2025-10-30 | The Westin Boston Seaport District, 425 Summer Street, Boston, MA, 02210, United States
Returning as the industry’s definitive forum from early discovery to clinical development, the 8th Annual TPD & Induced Proximity Summit is the world’s largest and longest-standing forum for proximity-based modalities, enabling you to fully immerse yourself in the breadth and depth of cutting-edge induced proximity therapeutic development.
Featuring key leaders such as Arvinas, Nurix Therapeutics, C4 Therapeutics, and innovative newcomers including Larkspur Bio, Magnet Biomedicine, TrimTech Therapeutics, as well as the co-founders of TPD, Craig Crews and Ray Deshaies, this is your ultimate meeting to hear the latest clinical data, forge strategic relationships, and capitalize on the huge opportunity for this modality to treat patients with high unmet clinical need.
Download the event guide for full details: https://ter.li/i9k5iz

2nd Patient Recruitment in Rare Disease Trials
2025-11-04 - 2025-11-06 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
The rare disease trial landscape stands at a pivotal tipping point. While unprecedented advances in trial design, digital tools, and regulatory flexibility are accelerating innovation like never before, the reality for patients remains stark: over 90% of rare diseases still lack an FDA-approved treatment. For many, clinical trials represent the only path to care, yet access remains uneven. Geographic isolation, diagnostic delays, and socioeconomic barriers continue to exclude many patients, especially from underserved communities, from participating in research.
Add to this the small, dispersed patient populations, high protocol complexity, and a shortage of disease-specific expertise, and it’s clear that traditional recruitment approaches no longer suffice.
Now in its second year, the Patient Recruitment for Rare Disease Trials Summit stands as the premier forum dedicated to closing this critical gap. Designed for leaders in Patient Recruitment, Clinical Operations, Patient Advocacy, and Medical Affairs this summit unites innovators reshaping rare disease trial access across the entire patient journey. Over three focused days in Boston, you’ll explore cutting-edge strategies spanning early patient identification to decentralized, patient-centric trial models that support participants from diagnosis through to long-term retention. Now is the time to accelerate creative recruitment strategies, deepen early patient engagement, and harness innovative technologies to ensure no rare disease patient is left behind in the race for transformative therapies.
You’ll join 70+ leaders from companies like Biogen, Takeda, Teva Pharmaceuticals, Genentech, Tenaya Therapeutics, and Sarepta Therapeutics, sharing what’s worked – and what hasn’t – when it comes to recruiting, retaining, and supporting rare disease patients through clinical trials.
Whether you’re running a trial for a rare neurological disorder, launching a global gene therapy study, or building support programs around ultra-small populations, the 2nd Patient Recruitment for Rare Disease Trials Summit is your strategic launchpad.
To know more visit: https://ter.li/qxs28b

LEAP HR: Emerging Biopharma
2025-11-04 - 2025-11-06 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
Funding pressures, regulatory shifts, global competition, and relentless layoffs are redefining the pre-commercial biopharma landscape. In this climate, agile, transparent, and people-first leadership is critical to keeping teams engaged, culture strong, and organizations moving forward.
LEAP HR: Emerging Biopharma is the only meeting built for senior HR leaders in this space. Over three days in Boston this November, you’ll join peers who understand your challenges, share proven solutions, and offer the community support you need to navigate disruption, adapt with resilience, and do more with less.
Leave equipped with fresh strategies to strengthen culture, re-energize your workforce, and lead through uncertainty with clarity, community, and confidence — ready to take on 2026 and beyond.
LEAP HR: Emerging Biopharma is a high-energy, high impact, fully immersive experience. We like to keep things short, snappy … and dare we say, fun? Welcome to a new era of conferences – one defined by case-study driven presentations, an ultra-niche HR life science community and our unique format, you will never need to attend any other conference.
Learn more: https://ter.li/o0nb7o

8th Neuropsychiatric Drug Development Summit
2025-11-09 - 2025-11-11 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
Industry’s Flagship Forum Capturing Advancements Across Discovery, Preclinical, Translational, Clinical & Regulatory Development of Innovative Neuropsychiatric Therapeutics
Uniting 150+ discovery, preclinical, translational, clinical, and regulatory leaders, the 8th Neuropsychiatric Drug Development Summit returns to provide you with an unrivaled opportunity to stay attuned to the latest progress while tackling industry’s most pressing challenges across a wide spectrum of mental health indications.

Recognized by key leaders as the “ideal size”, offering a “targeted audience” perfect for meaningful networking and collaboration, join thought leaders from Bristol Myers Squibb, AbbVie, Otsuka, Johnson & Johnson, Biogen, Lundbeck, Delix Therapeutics, Boehringer Ingelheim, and many more this September to revitalize the mental health drug development landscape.
Over the 3 day agenda, you’ll engage in deep-dive interactive workshops, roundtable discussions, data-driven presentations and structured networking activities to foster collaboration and gain the latest insights to truly advance your pipeline of next generation neuropsychiatric therapeutics.
Our attendees span discovery, in vivo pharmacology, translational medicine, clinical development, medical, regulatory affairs, academics, venture capitalists, and solution providers, ensuring that whatever part you play in transforming the mental health treatment and therapeutic landscape, you are surrounded by peers with the knowledge and capacity to support you.
When you join the Neuropsychiatric Drug Development Summit you can expect to:

Decipher the journey to ‘precision psychiatry’ through investigating the most progressive advancements in EEG and fluid-based markers
Discover innovative strategies to control placebo responses and bridge the translational gap to effectively analyze phenotypic behavior preclinically
Investigate the efficacy of standalone psychedelics vs when applied in conjunction with psychotherapy, and explore groundbreaking progress in novel non-hallucinogenic neuroplastogens
Review the latest advancements in new targets and mechanisms, including moving beyond atypical antidepressants and antipsychotics, to truly transform patient burdens

Plus, all new for 2025 is the EEG Focus Day which will support your efforts in utilizing EEG as a comprehensive and translational tool to guide your program through end-to-end development, and the new Investor’s Panel which will explore the catalysts driving deal-making momentum in the current neuropsychiatric and mental health R&D landscape.
So, what are you waiting for? Learn more about the summit today and explore the 40+ leading experts presenting at this year’s meeting, the array of sessions and bespoke workshops designed to support you, and the companies attending to advance neuropsychiatric therapeutics.
View the brochure now for all this and more: https://ter.li/g4f9aj

Transdermal and Microneedle Drug Delivery
2025-11-10 - 2025-11-11 | Hilton London Kensington, 179-199 Holland Park Ave, London, W11 4UL, United Kingdom
Have you considered how microneedle drug delivery systems could revolutionise the future of vaccine and drug administration?
This November, join SAE Media’s 4th Annual Transdermal and Microneedle Drug Delivery Conference. Engage with leading drug development and delivery experts in a dynamic, expert-led environment. Connect with forward-thinking innovators to explore cutting-edge case studies, breakthrough vaccine and therapeutic applications, and the evolving capabilities of transdermal and microneedle technologies. Transdermal and microneedle patches hold the potential to ‘go beyond the needle’ and transform pharmaceutical development—offering enhanced accessibility and long-term delivery solutions. With applications ranging from improved vaccine distribution to advanced diagnostics, these technologies are poised to reshape healthcare by increasing efficacy and expanding global access to life-changing treatments.
To know more click here.

7th Targeted Radiopharmaceuticals Summit Europe
2025-11-10 - 2025-11-12 | Mövenpick Hotel Amsterdam City Centre, Piet Heinkade 11, Amsterdam, 1019 BR, Netherlands
7th Targeted Radiopharmaceuticals Summit Europe
10–12 November 2025 | Amsterdam
Translating Novel Radiopharmaceutical Therapies to Transform the Medical Future

Now in its seventh year, the Targeted Radiopharmaceuticals Summit Europe returns to Amsterdam to bring together over 200 leaders in radiopharmaceutical therapy development. Designed to establish radiopharmaceuticals as a core pillar of oncology, this event is essential for professionals working across discovery, clinical development, and manufacturing.
Highlights of the 2025 Program:
More than 45 expert speakers from leading companies including Bayer, AstraZeneca, Novartis, Telix Pharmaceuticals, and more
Introduction of a third content track, covering:
Discovery & Preclinical
Translational & Clinical
CMC & Sourcing
Six in-depth workshops on key challenges including radiopharmaceutical design, dosimetry translation, and isotope supply
Key Speakers:
Thomas Birger Eden-Jensen, Head, External Supply Management TRP, Bayer
Mark Fielding, Director, CMC, Regulatory Affairs, TRP, AstraZeneca NEW SPEAKER
Isabel Jaco, Group Leader, RLT Drug Discovery, Novartis NEW SPEAKER
Sandra Uhlenbroich, Director, Discovery, Bicycle Therapeutics NEW SPEAKER
Frederic Fantino, Global Medical Affairs EMEA, Telix Pharmaceuticals NEW SPEAKER
Thijs Spoor, Chief Executive Officer, Perspective Therapeutics NEW SPEAKER
Sigal Kalmanson, Chief Executive Officer, Starget Pharma
Topics Include:
Novel target discovery, including SSTR3 and FAP
Isotope selection and supply chain resilience
Translating dosimetry into clinical studies
First-in-human study design and Phase 0 considerations
Scalable and compliant manufacturing strategies
This is the most comprehensive European agenda for targeted radiopharmaceuticals to date, built to accelerate asset development and address the sector’s most pressing challenges.
View the full program: https://ter.li/gowcuf
Hyperlink – https://ter.li/gowcuf

7th TIL Therapies Summit
2025-11-11 - 2025-11-13 | The Westin Boston Seaport District, 425 Summer Street, Boston, MA, 02210, United States
Now in its seventh year, the TIL Therapies Summit returns as the leading event dedicated to advancing tumor-infiltrating lymphocytes (TIL) therapies. Taking place November 11–13, 2025, in Boston (MA), this summit unites global experts across biopharma, academia, clinical practice, and manufacturing to accelerate the development and commercialization of next-generation TIL treatments.
Following the first-ever FDA approval of a TIL therapy in the U.S., and with regulatory decisions pending in Canada and Europe, the field is at a pivotal inflection point. The 7th TIL Therapies Summit offers a timely platform to explore how optimized TIL selection, engineering, and manufacturing can unlock scalable, potent treatments for solid tumors beyond melanoma.
The program is designed to tackle the most pressing challenges in TIL development, including:

Engineering TILs for improved persistence, potency, and specificity
Manufacturing innovations in closed systems to speed-up turnaround, and reduce IL-2 dependency
Clinical trial design and patient access strategies
Biomarker discovery and potency assay development
Real-world implementation and patient/provider perspectives

With 28+ expert speakers, 50+ attendees, and 8 hours of dedicated networking, the summit fosters a collaborative environment for sharing cutting-edge science, operational insights, and lived experiences. Attendees will hear from leading voices including:

Inge Jedema, Netherlands Cancer Institute
Jingwei Sun, Grit Biotechnology
Madan Jagasia, Obsidian Therapeutics
Micah Benson, KSQ Therapeutics
Michael Lotze, University of Pittsburgh
Roda Amaria, MD Anderson Cancer Center

You can see who else is speaking in this year’s program: https://ter.li/i4a730
Whether you’re preparing for your first clinical trial, scaling manufacturing, or navigating regulatory pathways, this summit delivers actionable insights for every stage of the TIL pipeline. Two new tracks focused on R&D and CMC ensure that both scientific and operational teams gain maximum value.
Unlike broader cell therapy events, the TIL Therapies Summit offers a focused, intimate setting where attendees can engage in meaningful dialogue, build lasting partnerships, and stay ahead of the curve in this rapidly evolving space.
If you’re committed to transforming the treatment landscape for solid tumors, the 7th TIL Therapies Summit is your must-attend event for 2025.
Find out more here: https://ter.li/nfdnks

9th Antifibrotic Drug Development Summit
2025-11-17 - 2025-11-19 | Wyndham Boston Beacon Hill, 5 Blossom St, Boston, MA, 02114, United States
2025 has seen a wave of positive anti-fibrosis advances. From Agomab’s Phase 2a results in fibrostenosing Crohn’s, Boehringer’s Phase 3 IPF data, Stanford’s TGF-β work in cardiovascular fibrosis, to over $3B in deals from Lilly, GSK, and others, it’s clear the antifibrotic drug development landscape is undergoing a seismic shift.
That’s why this year’s Antifibrotic Drug Development Summit is THE place to be this November. Learn from the industry’s premier experts at the forefront of fibrosis research, gain unmissable cross-fibrosis insights, and make unmatched connections with 80+ industry leaders from Pfizer, Eli Lilly, Novartis, Takeda and more!
Access this year’s incredible lineup of speakers
Join us this year to:

Unlock novel targets with advances in single-cell and spatial omics, immune-stromal interactions, and cross-tissue mechanisms, featuring insights from Harvard Medical School, Gilead Sciences, and AdaptVac
Strengthen translational confidence with precision-cut tissue slices, 3D models, and AI-driven biomarker strategies to bridge the gap between preclinical promise and clinical success
Design winning clinical programs with lessons from recent Phase 2 data, including Resmetirom’s approval for MASH fibrosis and emerging IPF signals from GRI Bio and Redx Pharma
Navigate the evolving landscape with expert perspectives on combination therapies, GLP-1 competition, and investor priorities to position your pipeline for partnerships and approvals

Don’t miss out – invite your colleagues to join you and take advantage of our early bird rates and group savings!
Secure my spot

Model-Informed Drug Development Summit
2025-11-18 - 2025-11-20 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
With the release of the draft ICH M15 guidelines and the FDA’s move to phase out animal testing, regulatory change is accelerating, solidifying Model-Informed Drug Development (MIDD) as a critical, non-negotiable tool in the drug development process.
The Model-Informed Drug Development Summit is the first and only industry-focused, 3-day strategic meeting dedicated to exploring how MIDD is transforming decision-making and driving drug development success. This is your opportunity to benchmark against industry leaders, refine your strategy, and future-proof your development approach.
Join senior experts in pharmacometrics, clinical pharmacology, PK/PD, and modeling from leading organizations including Pfizer, Third Rock Ventures, Johnson & Johnson, AbbVie, and more, as they uncover how MIDD is being used to:

Select better candidates earlier in development
Streamline or eliminate clinical trial phases
Personalize and optimize trial designs
Build stronger, data-driven regulatory submissions

Why Attend?

Unlock real-world case studies showing how MIDD accelerates timelines, cuts costs, and improves outcomes
Gain insight into how peers are implementing MIDD from discovery through to regulatory approval
Collaborate with cross-functional teams to exchange strategies and overcome shared challenges

With exclusive insights into ICH M15, practical applications across diverse therapeutic areas, and proven examples of success, this summit is your one-stop shop for unleashing the full potential of MIDD.
Learn more here: https://ter.li/unljt8

3rd LNP Characterization & Analytical Development Summit
2025-11-18 - 2025-11-20 | Hyatt Regency Boston Harbor, 101 Harborside Drive, Boston, MA, 02128, United States
3rd LNP Characterization & Analytical Development Summit
De-Risk Regulatory Submissions Through Smarter LNP Characterization
Curated in collaboration with leading analytical scientists and key LNP stakeholders, the 3rd LNP Characterization & Analytical Development Summit returns with new data, fresh insights, and an expanded speaker lineup. As the definitive forum for LNP analytics and characterization, this summit is your go-to platform for driving the development of safe, effective, and high-quality LNP-based drug products.
This highly focused, three-day agenda will equip analytical experts with the technical insights needed to:

Accelerate development timelines
Bridge critical analytical gaps
Streamline regulatory submissions for faster approval

Join over 90 industry leaders in analytics, characterization, assays, and CMC from organizations including Pfizer, Novo Nordisk, Prime Medicine, Tessera Therapeutics, GSK, Sanofi, and more.
Key Benefits of Attending:

Gain deep technical knowledge on cutting-edge LNP analytics
Discover strategies to overcome common characterization challenges
Align on regulatory expectations to support faster, smoother submissions
Network with peers tackling the same development and regulatory hurdles

With data-driven presentations and expert-led discussions, this is your opportunity to help define and implement robust analytical strategies that support the rapid development and approval of next-generation genomic medicines.
Learn more here: https://ter.li/ympfix

7th Myeloid-Directed Therapies Summit
2025-11-18 - 2025-11-20 | W Boston, 100 Stuart Street, Boston, MA, 02116, United States
The Only Industry-Dedicated Summit for Advancing Myeloid Cell Therapies in Oncology, Inflammation and Beyond…
Uniting leading experts from pharma, biotech, and academia, the 7th Myeloid-Directed Therapies Summit is the definitive event for anyone developing macrophage- and neutrophil-targeted therapies. As the field pushes beyond T-cells, this forum dives into myeloid reprogramming, cell state heterogeneity, and translational challenges to unlock next-generation immune modulation.
With breakthrough insights from Eli Lilly, AbbVie, Pfizer, AstraZeneca, and Faron Pharmaceuticals, and cutting-edge academic labs, this is your opportunity to explore clinical case studies, dissect failed monotherapy lessons, and gain clarity on patient stratification, trial design, and combination strategies.
Learn more: https://ter.li/by8e82

9th Dermatology Drug Development Summit
2025-11-18 - 2025-11-20 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
The 9th Dermatology Drug Development Summit is the definitive industry-led forum bringing together a driven community of experts pioneering innovative drug discovery and clinical strategies to improve long-term outcomes for patients with immuno-inflammatory disease. With disease heterogeneity and biomarker discovery fueling a new wave of research, and clinical pipelines facing intensifying competition, the need to develop differentiated, novel candidates has never been more critical.
As the field accelerates with clinical and commercial momentum, highlighted by Sanofi’s continued success with Dupixent, Corvus’ promising Phase 1 data on Soquelitinib, and landmark deals such as Gilead’s $1.7B inflammation partnership with LEO Pharma – this summit provides an essential platform to stay ahead of the curve. Returning this November, the meeting unites 120+ leading experts from pharma, biotech, and academia, all dedicated to overcoming the most pressing R&D bottlenecks in dermatology drug development.
Attendees will gain insights into the latest preclinical and clinical findings across both rare and common conditions, including atopic dermatitis, psoriasis, hidradenitis suppurativa, vitiligo, pemphigus nodularis, bullous pemphigoid, and alopecia areata. Sessions will explore the complexity of disease heterogeneity, emerging mechanisms of action, safety considerations, and the evolving regulatory landscape. With contributions from thought leaders at AbbVie, Sanofi, Takeda, Incyte, Merck, and other trailblazing organizations, discussions will span discovery, preclinical, translational, clinical, and medical affairs perspectives.
The program also offers a forward-looking exploration of the modalities reshaping dermatology pipelines, from bispecifics and biologics to oligonucleotides and beyond. By combining cutting-edge science with real-world clinical and strategic insights, the 9th Dermatology Drug Development Summit equips participants with the tools to accelerate innovation, navigate increasing competition, and ultimately deliver therapies that transform patient quality of life.
If you’d like to learn more about the summit, download the event guide or get in touch!

3rd Donor Selection & Cell Source Summit
2025-11-19 - 2025-11-20 | Westin Bayview San Diego, 1051 Columbia St, San Diego, CA, 92101, United States
Returning for its third year, the Donor Selection & Cell Source Summit is the only industry-dedicated forum focused exclusively on the strategic and scientific challenges of donor selection and cell sourcing for allogeneic therapies.
This summit brings together leading minds from biopharma, blood banks, apheresis providers, and cell therapy innovators to address one of the most critical bottlenecks in the development of scalable, off-the-shelf treatments.
With over 600 allogeneic clinical trials currently underway, the pressure to secure high-quality, consistent donor-derived starting material has never been greater. This summit provides a unique opportunity to explore how smarter donor screening, recruitment, and retention strategies can directly impact product quality, manufacturing scalability, and clinical success.
Attendees will gain actionable insights into:

Donor testing and screening protocols that improve product safety and consistency
Retention strategies to build reliable donor pools
Cryobiology and supply chain innovations that enhance cell viability and streamline logistics
Analytical development and quality control for robust characterization of starting material

See what other insights you can walk-away with in the program: https://ter.li/c2h7ym
The summit features expert speakers from leading organizations including Bristol Myers Squibb, Genentech, Allogene Therapeutics, ImmuneBridge, NKILT, Luminary Therapeutics, and many more offering a cross-functional perspective on how donor and source decisions shape the future of cell therapy.
Unlike broader cell therapy conferences, this event zeroes in on the upstream decisions that define downstream success. Whether you’re optimizing donor engagement, navigating regulatory complexities, or refining your sourcing strategy, the Donor Selection & Cell Source Summit provides the tools and connections to move your program forward.
Expect two days of deep scientific exchange, strategic discussion, and collaborative problem-solving in an intimate setting designed to foster meaningful dialogue. If you’re working to unlock the full potential of allogeneic therapies, this is the one event you can’t afford to miss.
For more information on the summit, view the program: https://ter.li/dc18d1

9th Complement-Based Drug Development Summit
2025-12-01 - 2025-12-03 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
Diving Into the Complement Cascade to Explore Intervention Points, Harnessing Biomarker Strategies to Identify Optimal Patient Populations, & Exploring the Therapeutic Opportunity from Rare Disease to Inflammation to Autoimmune Disease.
So far, 2025 has brought significant excitement and progress to the complement-based therapeutic landscape. Leading biopharma companies like Novartis, Annexon Biosciences and Omeros, are making significant clinical progress in PNH, AMD, IgAN and C3G, whilst key academics such as Michael Holers, Michael Brenner, and Brahm Segal continue to make discoveries in complement imaging, novel pathways, and new therapeutics areas such as oncology and transplantation.
The Complement-Based Drug Development Summit returns for its 9th year to unite the leading experts in complement biology and therapeutic development, from innovative biotech to impactful large pharma and academic experts. This meeting will harness the energy and dedication deepening the current understanding of the complement system to advance drug development in rare disease and beyond with patients at the forefront.
Join us at the 2025 meeting to gain insights from 20+ expert speakers covering the end-to-end complement-based drug development, from basic biology to diagnostics and clinical development.
Participate in three dedicated workshops for active discussion on key topics including the intracellular complement system, bispecific complement mediators, and innovative delivery of complement-based therapeutics to ensure delivery to the correct targets.
This comprehensive program spans a broad spectrum of renal, ophthalmic, neurological, and haematological indications, mirroring the shift in focus of the complement field from rare orphan indications to larger patient populations.
Join 80+ industry experts this December and access exclusive insights into therapeutic development across the complement field and bring actionable learnings and competitive intelligence back to your team.

7th Cell Therapy Analytical Development Summit
2025-12-01 - 2025-12-03 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
Recognized as the industry’s leading forum for cell therapy analytical, quality control, assay, and CMC professionals, the 7th Cell Therapy Analytical Development Summit, returns to Boston to provide the expertise needed to prepare your teams for clinical and commercial readiness. Hear directly 80+ experts from Takeda, Arsenal Bio, Bayer, Genentech, Adicet Bio, Quell Therapeutics, and the National Institute of Health, as they share proven strategies, innovative technologies and best-in-class approaches to enhance your product safety and quality, ahead of regulatory approval.
Now combined with the previously separate, Cell Therapy Potency Assay Summit, this meeting provides you with an even more comprehensive agenda, covering the full landscape of analytical development, across early- and late-stage assay development tracks. Join us this December to fast-track the next era of safe, potent and robust cell therapies to market!
For more information, please visit https://ter.li/9uagdj

8th RNA-Targeted Drug Discovery & Development Summit
2025-12-02 - 2025-12-04 | The Westin Boston Seaport District, 425 Summer Street, Boston, MA, 02210, United States
RNA-targeting small molecules are rapidly emerging as a powerful therapeutic reality. From modulating splicing to directly binding RNAs, these molecules offer a revolutionary approach to treating previously undruggable diseases across neurodegenerative, cancer and rare disorders. In 2025 alone, the field has seen major collaborations, including Wayfinder Biosciences with Daiichi Sankyo, Ono Pharmaceutical with Reborna Biosciences, and xFOREST with Astellas Pharma—signaling growing momentum and industry confidence.
Now in its 8th year, the RNA-Targeted Drug Discovery & Development Summit returns as the only dedicated industry forum addressing the unique challenges of RNA-targeted drug development across splice modulators, covalent drugs, proximity inducers and direct RNA binders.
Join 25+ world-class speakers from leaders like PTC Therapeutics, ReviR Therapeutics, Remix Therapeutics, Rgenta Therapeutics, Arrakis Therapeutics and more this December to gain the connections, tools and scientific firepower needed to bring your RNA-targeted therapeutics to clinic and beyond.
Step into the future of RNA-targeted drugs at the 8th RNA-Targeted Drug Discovery & Development Summit. With 75% new speakers from 2024 and 50% of the speakers sharing new data, this summit is set to offer the latest data and fresh insights on small molecules targeting RNA.
This year, join 80+ experts in RNA biology, drug discovery, medicinal chemistry, and structural biology to gain the latest data on visualizing dynamic RNA structures, identifying functional binders, improving selectivity, enhancing delivery stability and achieving oral bioavailability.
Whether you’re focused on RNA splice modulators, covalent binders, proximity inducing drugs, or direct RNA binders this event will give you the tools and insights to fast track the discovery of functional binders and accelerate your pipeline of RNA-targeted small molecules to the clinic.
Connect with your global community at the world’s only meeting for RNA-targeted drug experts.
To know more visit: https://ter.li/rcvdor

2nd Innovation in Obesity Therapeutics Summit
2025-12-02 - 2025-12-04 | DoubleTree by Hilton Hotel San Diego – Mission Valley, 7450 Hazard Center Dr, San Diego, CA, 92108, United States
The 2nd Innovation in Obesity Therapeutics Summit will return to San Diego this December. Hear from the titans of the pharmaceutical industry, including Novo Nordisk, Eli Lilly and Boehringer Ingelheim, who will share their groundbreaking research and strategies. The pressure is on to develop best-in-class treatments that transform patient lives.
Don’t miss this pivotal opportunity to network with 60+ experts in the field of obesity, forge crucial collaborations, and be part of the solution.
Find out more here: https://ter.li/vnapww

2nd Cell & Gene Therapy Regulatory Affairs Summit
2025-12-02 - 2025-12-04 | Washington Marriott Capitol Hill, 175 L St NE, Washington, WA, 20002, United States
With major FDA changes already reshaping the regulatory landscape – and global agencies ramping up scrutiny – 2025 is a pivotal year for cell and gene therapy regulatory professionals. With CBER leadership changes, new FDA draft guidance on post-approval CMC, and potency assays facing heightened scrutiny, the environment is rapidly evolving. Global efforts to align expectations are also gaining momentum, with ANVISA and Health Canada joining harmonization initiatives, and ICH Q12 implementation for CGTs underway.
The 2nd Cell & Gene Therapy Regulatory Affairs Summit is the only industry-led event focused exclusively on CGT regulatory strategy. Join 80+ experts this December in Washington, D.C. for real-world case studies, insights from regulators, and deep dives into IND-to-BLA planning, global alignment, and emerging modalities.
If you’re navigating nonclinical, clinical, or CMC submissions, this is your essential forum to stay ahead of shifting expectations and accelerate CGT approvals in 2025 and beyond.
Find out more: https://ter.li/c211fx

Designing the AI-Enabled Biopharma Workforce Summit
2025-12-02 - 2025-12-03 | W Boston, 100 Stuart Street, Boston, MA, 02116, United States
The World’s Only Industry-Specific Forum on AI-Oriented Skills-Centric Workforce Transformation in Life Sciences
Most roles in biopharma organizations will undergo an AI-driven transformation in the coming years. But exactly how that transformation manifests itself, in what jobs, with what skills, and across what proportion of our workforces is not yet fully clear.
What is clear, though, is that the future depends on what we do now. The most forward-thinking companies already know that innovation doesn’t just happen at the bench, it also takes place company-wide in working out what needs to be done, how, and by whom.
They are building future workforce capability faster by reassessing the needs of each department and fundamentally rethinking what work is best done by people versus what can be automated with technology. For the first time, this forum will shine a light on how this is done.
Taking part will help you approach organizational design with a new perspective which is skills centric, rather than job centric and allow you to walk away with a new skills taxonomy that will help you deliver more productivity and more innovation from fewer people in less time.
Download the Agenda

5th Applied Biocatalysis & Enzyme Engineering Summit
2025-12-02 - 2025-12-04 | Washington Marriott Capitol Hill, 175 L St NE, Washington, WA, 20002, United States
Navigate New FDA Leadership, Harness AI-Powered Submissions & Align Technical Innovation with the Latest Nonclinical, Clinical & CMC Guidance to Overcome Regulatory Challenges and Accelerate Your Path to Clinic & Market
With major FDA changes already reshaping the regulatory landscape – and global agencies ramping up scrutiny – 2025 is a pivotal year for cell and gene therapy regulatory professionals. With CBER leadership changes, new FDA draft guidance on post-approval CMC, and potency assays facing heightened scrutiny, the environment is rapidly evolving. Global efforts to align expectations are also gaining momentum, with ANVISA and Health Canada joining harmonization initiatives, and ICH Q12 implementation for CGTs underway.
The 2nd Cell & Gene Therapy Regulatory Affairs Summit is the only industry-led event focused exclusively on CGT regulatory strategy. Join 80+ experts this December in Washington, D.C. for real-world case studies, insights from regulators, and deep dives into IND-to-BLA planning, global alignment, and emerging modalities.
If you’re navigating nonclinical, clinical, or CMC submissions, this is your essential forum to stay ahead of shifting expectations and accelerate CGT approvals in 2025 and beyond.
Learn more: https://ter.li/c211fx

6th Gene Therapy for Ophthalmic Disorders Summit
2025-12-02 - 2025-12-04 | DoubleTree by Hilton Raleigh Midtown, 2805 Highwoods Blvd, Raleigh, NC, 27604, United States
The 6th Gene Therapy for Ophthalmic Disorders Summit returns to Raleigh, North Carolina, as the leading industry forum dedicated to accelerating the development of gene therapies for both rare and common eye diseases. With irreversible vision loss progressing rapidly in many conditions, gene therapy continues to emerge as a critical one-time intervention that can preserve and restore sight for patients in need.
Momentum in 2025 is stronger than ever. Kriya Therapeutics is advancing its preclinical pipeline, Opus Genetics and SpliceBio are progressing into early trials, while Ocugen, 4D Molecular Therapeutics, and AbbVie are racing toward BLA approval. Against this backdrop of progress, challenges around endpoint selection, funding strategies, and safe delivery methods remain at the forefront. The summit provides a unique platform to tackle these issues head-on and drive forward meaningful breakthroughs.
Attendees will gain access to exclusive data and insights, including preclinical updates from Opus Genetics, Coave Therapeutics, and Axovia Therapeutics, alongside pivotal 2025 clinical progress shared by Ocugen, Adverum Biotechnologies, and Beacon Therapeutics. A major highlight is the Interview the Investor session with James Kasuboski, Partner & Head of Research at Luma Group, where attendees will hear directly from investors on the criteria shaping ophthalmic gene therapy funding and strategies for building sustainable development approaches.
Additional sessions will spotlight patient-led regulatory engagement, comparative analyses of delivery approaches, and strategies for optimizing trial design and patient retention. With a carefully balanced agenda – equally split between preclinical and clinical content – this meeting provides a comprehensive view of the ophthalmic gene therapy pipeline.
Featuring 18+ senior expert speakers, 3+ hours of clinical data, 2+ hours of preclinical research, and 6+ hours of networking opportunities, the summit unites biopharma leaders, investors, and innovators to accelerate progress from IND through to late-stage clinical development.
Join us in Raleigh to connect with decision-makers across the ophthalmic gene therapy value chain, uncover the next wave of breakthroughs beyond Luxturna, and ensure your therapy reaches patients faster.
View the full event program on our website here: https://ter.li/0duhtz

3rd Cell Therapy for Autoimmune Disease Summit
2025-12-02 - 2025-12-04 | Sheraton Philadelphia Downtown, 201 N 17th Street, Philadelphia, PA, 19103, United States
Ever since the field-defining studies in Nature Medicine and the New England Journal demonstrated that cell therapies could hold lasting potential in lupus and beyond, the field has grown from strength to strength. With a surge of billion-dollar investments, the release of new groundbreaking data, and recent real-world clinical progression, the autoimmune cell therapy field is poised for clinical and commercial success.
The 3rd Cell Therapy for Autoimmune Disease Summit (December 2-4 | Philadelphia, PA) returns at a pivotal time, providing first-hand insights and case studies needed to keep your team ahead in this fast-evolving space. Reconnect with 130+ scientific pioneers, with expertise spanning CAR-T, Treg, in vivo and NK cell therapies, as they unveil the latest clinical data and cutting-edge innovations redefining the chronic care of autoimmune indications.
Access Your Brand-New 2025 Agenda Copy!
Learn directly from industry titans including Cabaletta Bio, Kyverna Therapeutics, Umoja Biopharma, Cartesian Therapeutics, Century Therapeutics, Artiva Biotherapeutics and Novartis, to benchmark your current strategies and gain a competitive edge amongst your peers to accelerate your lead candidate from preclinical innovation to clinical success.
Whether you are preparing for your first clinical trials, or making the transition into later phases, our carefully curated two-tracked agenda (now expanded to the Workshop Day!) has content tailored for you.

Preclinical & Translational: Address challenges in antigen selection, delve into autologous and allogeneic translational strategies, and discuss alternatives to B-cell depletion, to bring the next wave of therapies to the clinic.
Clinical: Unpack trial design, evaluate long-term clinical outcomes, share regulatory strategies, and learn how to operationalize studies for broader patient access.

With cell therapy companies increasingly targeting autoimmune diseases, and autoimmune companies continuing to embrace cellular approaches, ensure you join the industry’s definitive meeting committed to transforming the promise of cell therapies in autoimmunity into reality.
Event Guide | Register | Learn More

14th Tumour Models Summit London
2025-12-03 - 2025-12-04 | Park Plaza Victoria London, 239 Vauxhall Bridge Road Pimlico, London, SW1V 1EQ, United Kingdom
With the European oncology market increasingly focused on emerging modalities, highlighted by AbbVie’s recent licensing agreement with Ichnos Glenmark Innovation for their trispecific antibody, Boehringer Ingelheim’s partnership with Tempus to advance their cancer pipeline and the FDA’s new roadmap and the EMA encouraging drug developers to use non-animal tests in submissions, there has never been a more important year to stay up to date with the latest innovations in tumour modelling.
As the longest-standing forum from the world-renowned Tumour Models event series, the 14th Tumour Models Summit London returns to unite 130+ tumour modelling experts from pharma, biotech, and model providers from across the UK and Western Europe to soundboard recent model selection strategies with the goal of bridging the translational gap to the clinic.
Download the event guide for full details: https://ter.li/hsztzb
